BSE: 524768
EMMESSAR BIOTECH & NUTRITION L
Operates two reported segments on BSE — a small Healthcare (biotech/nutrition) business and rental income from a leasehold land holding — and is classified under Commodity Chemicals. In FY26, revenue from operations (the Healthcare segment) fell about 39% year-on-year to ₹37.08 lakh from ₹61.09 lakh, while total income of ₹240.66 lakh was supported by ₹165.31 lakh of rent on leasehold land booked as other income. Segment data for the year ending March 2026 shows Healthcare at ₹0.0928 crore, Rent on Leasehold Land at ₹0.4133 crore and Others at ₹0.0601 crore of period segment revenue. Profit after tax nevertheless rose 37.8% to ₹43.59 lakh (from ₹31.62 lakh) largely because the tax expense dropped from ₹64.20 lakh to ₹14.37 lakh. The company carries no debt and holds total assets of ₹9.5301 crore; employee cost of ₹1.0791 crore is several times its revenue from operations, indicating the core biotech activity is a very small contributor relative to fixed costs. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Healthcare, Rent on Leasehold land, Others. Very small BSE-listed entity with a declining biotech core propped up by steady leasehold rent income; low operating scale, no debt.
Exhibit 1: Financial summary, – (all audited; no estimate years)
| ₹ crore · consolidated |
|---|
| Revenue |
| EBITDA (ex other income) |
| margin % |
| Owners' profit |
| EPS, as reported (₹) |
| ROE % · ROCE % |
| Debt / equity (x) |
| Cash from operations |
| Capex |
Exhibit 2: Quarterly performance, last 1 quarters
| ₹ crore | Q1 FY27 |
|---|---|
| Revenue | 0 |
| Profit before tax | 0 |
| Net profit | 0 |
| EPS (₹) | 0.26 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| TATA CHEMICALS LTD | 15,351 | — | 0.69 | 139.2 | (7.7) | (5.0) | 7.4 | 14.4 |
| DEEPAK FERTILIZERS & PETR | 14,679 | 14.9 | 1.97 | 11.1 | 9.9 | 8.4 | 14.6 | 26.1 |
| GUJ NAR VAL FER & CHEM L | 7,529 | 7.3 | 0.83 | 5.4 | 8.9 | 10.3 | 8.7 | 22.1 |
| TANFAC INDUSTRIES LTD. | 6,923 | 56.6 | 18.55 | — | 18.8 | 24.3 | — | 16.0 |
| GUJARAT ALKALIES & CHEM | 4,105 | 61.8 | 0.79 | 8.7 | (0.0) | 0.7 | 12.4 | 18.4 |
| GHCL LIMITED | 3,565 | 7.8 | 1.00 | 4.7 | 13.3 | 16.6 | 1.1 | 23.9 |
| GRAUER & WEIL IND LTD | 3,543 | 21.6 | 3.28 | 14.4 | 15.2 | 19.2 | 14.5 | 20.4 |
| J.G.CHEMICALS LIMITED | 2,179 | 29.0 | 4.03 | 22.2 | 12.7 | 16.9 | — | 11.5 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 88.4 | 17.4 | 46 of 50 | 8% |
| EBITDA margin | 314.3 | 13.3 | 3 of 58 | 97% |
| Market cap | 11 | 98 | 57 of 66 | 14% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 23 Oct 2026 · Board meeting for September 2026 quarterly results | results | low | — | — |
| 9 Oct 2026 · Q2 FY27 dematerialisation compliance certificate filed with BSE | compliance | minimal | — | — |
| 2 Oct 2026 · Newspaper ad published for re-lodgement of physical share transfers | compliance | minimal | — | — |
| 29 Sept 2026 · Trading window closed from Oct 1 until Q2 FY26 results disclosure | compliance | minimal | — | — |
| 29 Sept 2026 · 34th AGM 2026 voting results: All 4 resolutions passed | board shareholder meetings | low | — | — |
| 29 Sept 2026 · 34th AGM held via video conferencing; 4 resolutions transacted including MD reappointment | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Newspaper ads confirming 34th AGM notice filed with BSE | compliance | minimal | — | — |
| 4 Sept 2026 · Annual Report and AGM Notice sent to shareholders without registered email | compliance | minimal | — | — |
| 4 Sept 2026 · Letter to shareholders without registered email about 34th AGM and Annual Report | compliance | minimal | — | — |
| 4 Sept 2026 · Annual Report and AGM Notice for FY2025-26 submitted | results | high | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.